ANTX
AN2 Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.89
−1.01%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | 77.0K |
| Gross Profit | — | — | — | — | (77.0K) |
| Operating Expenses | |||||
| R&D Expense | 26.6M | 24.8M | 40.5M | 54.9M | 29.5M |
| SG&A Expense | 12.2M | 13.3M | 14.1M | 14.8M | 12.8M |
| General & Admin Expense | 12.2M | 13.3M | 14.1M | 14.8M | 12.8M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 38.8M | 38.1M | 54.6M | 69.6M | 42.2M |
| Cost and Expenses | 38.8M | 38.1M | 54.6M | 69.6M | 42.3M |
| Operating Income (EBIT) | (38.8M) | (38.1M) | (54.6M) | (69.6M) | (42.3M) |
| Non-Operating | |||||
| Interest Income | 2.5M | 2.9M | 5.5M | 4.9M | 1.4M |
| Interest Expense | — | — | — | — | 514.0K |
| Net Interest Income | 2.5M | 2.9M | 5.5M | 4.9M | 837.0K |
| Other Non-Op Income/Expense | 2.5M | 2.9M | 3.2M | 4.9M | 1.3M |
| Non-Operating Income (excl Interest) | (1.2M) | (2.9M) | (3.2M) | (4.9M) | (1.3M) |
| EBT (Pre-Tax Income) | (36.3M) | (35.2M) | (51.3M) | (64.7M) | (41.0M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (36.3M) | (35.2M) | (51.3M) | (64.7M) | (41.0M) |
| Earnings from Cont. Ops | (36.3M) | (35.2M) | (51.3M) | (64.7M) | (41.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (36.3M) | (35.2M) | (51.3M) | (64.7M) | (42.8M) |
| Per Share | |||||
| Basic EPS | ($1.07) | ($1.16) | ($1.72) | ($2.74) | ($2.79) |
| Diluted EPS | ($1.07) | ($1.16) | ($1.72) | ($2.74) | ($2.79) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 44.8M | 30.2M | 29.8M | 23.6M | 15.3M |
| Diluted Shares Outstanding | 44.8M | 30.2M | 29.8M | 23.6M | 15.3M |
| Profitability Metrics | |||||
| EBITDA | (37.6M) | (35.2M) | 3.2M | 4.9M | (40.9M) |
| D&A | — | — | 54.6M | 69.6M | 77.0K |
| EBIT | (37.6M) | (35.2M) | (51.3M) | (64.7M) | (41.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026